Journals / MN Kardiyoloji / 2008 / Cilt: 15 - Sayı: 4

Intracoronary Thrombus Complete Dissolving with Tirofiban Treatment

Koroner İçi Trombüsün Tirofiban Tedavisi ile Tam Çözülmesi

Pages
252–255
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Control aniogram obtained seven days later showed complete dissolving of the coronary thrombus.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acute coronary syndrome (ACS) are usually associated with intracoronary thrombus superimposedon disruption of atherosclerotic plaque.
📊
Key Findings & Data:A 59 year-old famele was admitted to our clinic with chestdiscomfort.
💡
Conclusion & Impact:Control aniogram obtained seven days later showed complete dissolving of the coronary thrombus.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Acute coronary syndrome (ACS) are usually associated with intracoronary thrombus superimposedon disruption of atherosclerotic plaque. A 59 year-old famele was admitted to our clinic with chestdiscomfort. He has had a history of chest pain at rest for three days. The admission electrocardiogram (ECG) showed minimal ST segment elevation, QS wave and T wave inversion in leads DII, DIIIand aVF, and T wave inversion in leads V3-6. Coronary cineangiography showed a massive intracoronary thrombus, which completely occluded the distal part of the right coronary artery. Percutaneouscoronary intervention was not performed due to massive thrombus. Then, Tirofiban treatment(0.4?g/kg/min bolus) over 30 minutes followed by 0.1?g/kg/min for 72 hours was begun. Control aniogram obtained seven days later showed complete dissolving of the coronary thrombus.

Özet

Akut koroner sendrom (AKS) genellikle yırtılan aterosklerotik plağın üzerinde oluşan koroner içi trombusla birliktedir. Kliniğimize 59 yaşında bir bayan hasta sternum üzerinde baskı şeklinde bir rahatsızlık hissi ile başvurdu. Üç gündür istirahatte göğüs ağrısı olduğu öğrenildi. Başvuru elektrokardiyografi (EKG)'sinde DII,DIII ve aVF derivasyonlarında minimal ST segment yüksekliği, QS ve T dalga negatifliği ve V3-6 derivasyonlarında T negatifliği vardı. Yapılan koroner anjiyografisinde sağ koroner arterindistal kısmı yoğun trombüsle tam tıkalı olduğu görüldü. Yoğun trombüsten dolayı perkütan koronergirişim düşünülmedi. Daha sonra 0.4?g/kg/dakika 30 dakika yükleme dozu takiben 0.1?g/kg/dakikagidecek şekilde 72 saat tirofiban tedavisine başlandı. Yedinci günde yapılan kontrol anjiyografisindekoroner içi trombüsün tamamıyla çözüldüğü görüldü.

🔖

Cite This Article

ALYAN, Ö., ALTINTAŞ, B., KARAHAN, Z., İYEM, H., ALAN, S. (2008). Intracoronary Thrombus Complete Dissolving with Tirofiban Treatment. MN Kardiyoloji, Cilt: 15 - Sayı: 4, 252–255. https://ajindex.com/articles/297475

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N engl J Med 1992; 326: 310-18.
  2. Mizuno K, Satumora K, Miyamoto A. Angioscopic evalua- tion of coronary artery thrombi in acute coronary syn- dromes. N Engl J Med 1992; 326: 287-91. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-Wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
  3. Zhao XQ, Theroux P, Snapinn SM, Sax FL; for the PRISM- PLUS Investigators. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-Wave myocardial infarction. Circulation 1999; 100: 1609-15.
  4. Coller BS, Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42. The CAPTURE Investigators. Randomized placebo-con- trolled trial of abciximab before and during coronary in- tervention in refractory unstable angina: the CAPTURE trial. Lancet 1997; 349: 1429-35.
  5. Xiao Z, Theroux P, Frojmovic M. Modulation of platelet- neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thromb Haemost 1999; 81: 281-5.
  6. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abcix- imab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percu- taneous coronary interventions: the EVEREST trial. J Am Coll Cardiol. 2006; 47: 522-8.
  7. Danzi GB, Sesana M, Capuano C, Mauri L, Predolini S, Baglini R. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention. Int J Cardiol. 2006;107:241-6.
  8. Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide dur- ing percutaneous coronary intervention in acute coro- nary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.Circulation;106:1470-6.
  9. Chen SM, Hsieh YK, Guo GB, Fang CY, Yip HK, Wu CJ, et al. Angiographic and clinical outcome in ST-segment eleva- tion myocardial infarction patients receiving an adjunc- tive double bolus regimen of tirofiban for primary percu- taneous coronary intervention. Circ J. 2006; 70: 536-41.